V8 Peptides — Engineered Performance
Research Library
IGF-1 LR3 Structure: Sequence Changes Explained
IGF-1 LR3Chemistry

IGF-1 LR3 Structure: Sequence Changes Explained

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What structural changes make IGF-1 LR3 different from native IGF-1? Two edits to the 70-residue native sequence. Glutamate at position 3 is replaced by arginine (the R3), and a 13-residue extension is added at the N-terminus (the Long), giving 83 residues and a mass near 9.1 kDa. Both changes sit in the N-terminal region of the B domain, which contributes to binding by IGF-binding proteins but not to the main receptor contact surface, so the analog binds binding proteins weakly while still activating the IGF-1 receptor. The three disulfide bonds of the native fold are retained.

The IGF-1 LR3 explainer introduces the two edits that define the analog. This article goes one level deeper into the structure: how native IGF-1 is organized, where the edits sit, which interactions each edit affects, and how the analytical identity of the molecule follows from its sequence. It is written for researchers who read a sequence or a mass spectrum and want to know why it looks the way it does. For laboratory research use only; not for human consumption.

Native IGF-1: a compact, three-disulfide protein

Human IGF-1 is a single-chain protein of 70 residues and about 7.65 kDa. Its sequence is organized into four domains named B, C, A and D, a layout inherited from proinsulin, to which it is structurally related. The B and A domains form the folded core that packs against each other and supply most of the receptor-binding surface; the C domain connects them and the short D domain extends past the A domain. In place of proinsulin's cleaved C peptide, IGF-1 keeps its C domain, which is one reason it is a single chain.

Six cysteines pair into three intramolecular disulfides, conventionally numbered Cys6–Cys48, Cys18–Cys61 and Cys47–Cys52. These bonds hold the B and A domains together. Reviews of IGF receptor structure and ligand binding describe how the surface of this fold engages the receptor (Adams et al., 2000), and the receptor signaling that follows is summarized in Hakuno and Takahashi (2018).

Domain map of the native protein

The domain layout can be summarized as follows, using native numbering.

DomainApproximate residuesRole in the foldRelevance to the analog
B1–29Packs against the A domain; carries the N-terminal region and part of the receptor surfaceSite of the Glu3-to-Arg change; extension attaches before residue 1
C30–41Connecting loop; part of the receptor-binding surface and a contact for some binding proteinsUnchanged
A42–62Second helical core domain; two of the three disulfides link it to BUnchanged
D63–70Short C-terminal extensionUnchanged

Because only the first block of the B domain is edited, most of the molecule is identical to native IGF-1, which is why antibodies, receptor assays and signaling readouts developed for IGF-1 usually work with the analog as well, with the caveat that an antibody raised against the N-terminus can be affected by the edit.

The Glu3-to-Arg substitution

Position 3 is in the extreme N-terminal stretch of the B domain, which in native IGF-1 begins Gly-Pro-Glu. Replacing the acidic glutamate with a basic arginine changes the local charge by two units. Structure–function studies from the late 1980s, including the analog panel of Bayne and colleagues (1988), showed that changes near the N-terminus of IGF-1 reduce affinity for the serum binding proteins without abolishing receptor binding, which is the observation that led to engineered variants with that property. The reported consequence is that the R3 analog is more potent than native IGF-1 in cells and animals that contain binding proteins (Tomas et al., 1992; Tomas et al., 1993).

The 13-residue N-terminal extension

The Long part of the name refers to a 13-residue extension added before the native Gly1. The extension lengthens the protein from 70 to 83 residues and adds about 1.5 kDa. It sits in a flexible position outside the folded core and is not expected to disturb the core's packing, but it adds to the steric and charge changes at the N-terminus that reduce binding-protein interaction. The related des(1–3) variant removes the same region instead of extending it, and animal studies have compared the variants side by side (Tomas et al., 1992). Whether each change contributes equally has to be read from the binding data in each paper rather than assumed.

FeatureNative IGF-1IGF-1 LR3IGF-1 DES (1-3)
Residues708367
Approx. mass7.65 kDaabout 9.1 kDaabout 7.4 kDa
Position 3GluArgDeleted (with residues 1 and 2)
N-terminusGly-Pro-Glu…13-residue extension, then Gly-Pro-Arg…Begins at residue 4
Disulfide bonds333
Binding-protein affinityHighMarkedly reducedMarkedly reduced
Receptor activationYesYesYes

The side-by-side layout is the logic of the DES comparison article, IGF-1 LR3 vs IGF-1 DES, which covers potency and handling differences.

What the edits do not change

The edits are N-terminal. They do not touch the A-domain or the C-domain, they leave all six cysteines in place, and they keep the receptor-contact surface intact. This is the structural basis for the analog's retained activity at the IGF-1 receptor, and it is why mechanism studies regard LR3 as a ligand with the same signaling output as native IGF-1 but different bioavailability in binding-protein-rich systems. The signaling side is in the research overview.

From sequence to analytical identity

The edits determine what an analytical check should find. The theoretical mass of the analog follows from its sequence, and the formula given on the product page, C400H625N111O115S9, corresponds to an intact, oxidized (disulfide-bonded) molecule. The nine sulfur atoms agree with six cysteine sulfurs plus three methionines, a count that is easy to check against the sequence. Intact-mass spectrometry should return a value near the theoretical mass of the correctly folded protein, and any extra peaks, such as +16 Da increments, point to oxidation (Aebersold and Mann, 2003 describe the technique's general logic). A peak at the right mass does not prove correct disulfide pairing, because isomers share the same mass, which is why peptide mapping under non-reducing conditions or a bioassay is used as well. The purity side of this is covered in the IGF-1 LR3 purity testing guide.

Practical consequences for assays

Reagents that recognize IGF-1 can behave differently with the analog depending on where they bind. A receptor-based assay generally works the same way for both because the receptor surface is unchanged. An immunoassay whose antibody recognizes the N-terminal region may under-detect the analog or fail on it, while an antibody directed at the A or C domains is more likely to cross-react. Mass-based methods are unaffected by this issue and distinguish native IGF-1 from the analog readily because of the roughly 1.5 kDa difference. When a sample might contain both, for example conditioned medium from cells that make native IGF-1 while the analog is added, choose a readout that separates them, and validate it against both standards before relying on it.

Why structure matters for handling

The structure also explains the handling rules. A folded, disulfide-bonded protein is vulnerable to unfolding at air–liquid interfaces, to disulfide exchange at alkaline pH and to adsorption at low concentration. These vulnerabilities are why the reagent is reconstituted gently, dispensed into low-binding tubes and aliquoted; the steps are laid out in how to reconstitute a lyophilized peptide and the reconstitution calculator supports the concentration arithmetic. Reviews of protein stability such as Manning and colleagues (2010) give the chemical background.

Reading a structure paper critically

When reading a study that compares analogs, check the following.

  • Whether numbering refers to the native sequence or includes the extension, because positions shift by thirteen.
  • Whether potency is reported as receptor binding, binding-protein binding or a cell response, since the three can move independently.
  • Whether the protein source was recombinant or synthetic, as folding yields differ.
  • Whether the binding-protein content of the assay was defined; the analog's advantage grows with binding-protein concentration.
  • Whether the comparison used the same mass or the same molar amount, since the analog is about 20% heavier than native IGF-1.

Common misconceptions

Three ideas recur in search results and are worth correcting. First, the "long" extension is not a different protein attached to IGF-1; it is a short peptide segment added at one end. Second, LR3 is not a shortened or truncated form; DES is. Third, a higher potency in culture does not imply a different receptor or pathway. All three follow directly from the structural facts above, and checking a claim against the sequence and the mass is usually the quickest way to catch a mislabeled or misdescribed product.

Related reading

Frequently asked questions

What does LR3 stand for?

Long R3: a 13-residue extension at the N-terminus (Long) and an arginine replacing the glutamate at position 3 (R3).

How many amino acids does IGF-1 LR3 have?

83, compared with 70 for native IGF-1. The mass is roughly 9.1 kDa.

Does the extension change the receptor-binding surface?

The edits are N-terminal and outside the main receptor-contact surface, which is consistent with the retained receptor activity reported for the analog.

How many disulfide bonds does it have?

Three, as in native IGF-1, from six cysteines.

Why do the edits reduce binding-protein binding?

The N-terminal region contributes to interaction with IGF-binding proteins, so charge and steric changes there weaken the interaction; structure–function studies from the 1980s established this region's role.

What is the difference between LR3 and DES?

LR3 is longer than native IGF-1 and changed at position 3; DES is shorter, with the first three residues removed. Both bind binding proteins poorly.

What formula is listed for the product?

The product page lists C400H625N111O115S9.

Does a correct mass prove correct folding?

No. Disulfide isomers have identical mass, so folding is checked by non-reduced mapping or by a bioassay.

Why does numbering differ between papers?

Some papers number from the native Gly1 and others include the extension, which shifts positions by thirteen.

Is the analog a different pathway activator?

No. It engages the same receptor and downstream pathways as native IGF-1; its distinguishing feature is binding-protein avoidance.

Related reading: IGF-1 and Tissue Repair Research: What Models Show, IGF-1 LR3 vs Des(1-3) IGF-1: Choosing an Assay Analog, IGF-1 LR3 vs Standard IGF-1: Binding Proteins in Culture.

References

  1. Bayne ML, Applebaum J, Chicchi GG, et al. Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 IGF receptor. J Biol Chem. 1988;263(13):6233-6239. doi:10.1016/s0021-9258(18)68777-0
  2. Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992;282:91-97. doi:10.1042/bj2820091
  3. Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. doi:10.1677/joe.0.1370413
  4. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050-1093. doi:10.1007/pl00000744
  5. Hakuno F, Takahashi SI. 40 years of IGF1: IGF1 receptor signaling pathways. J Mol Endocrinol. 2018;61(1):T69-T86. doi:10.1530/jme-17-0311
  6. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422(6928):198-207. doi:10.1038/nature01511
  7. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.